Skip to main content
SpringerLink
Log in

Ranolazine (Ranexa®) in the treatment of chronic stable angina

  • Review
  • Published:
Advances in Therapy Aims and scope Submit manuscript

Abstract

Ischemic heart disease is the major cause of morbidity and mortality in the Western world. Patients often suffer a reduction in quality of life due to chronic stable angina, but therapeutic options can be limited due to concerns for heart rate and blood pressure, as well as side effect profiles. Even revascularization therapy has its limitations and newer agents are required to help in this battle for symptomatic relief. Ranolazine (Ranexa®, A. Menarini Pharma UK, High Wycombe, UK) is a drug with a novel mechanism of action that has been shown in several large trials to be an efficacious adjunctive agent in reducing symptoms of chronic stable angina. It is thought to work by inhibiting the late sodium current in cardiac myocytes, thereby reducing sodium and calcium overload that follows ischemia. This improves myocardial relaxation and reduces left ventricular diastolic stiffness, which in turn enhances myocardial contractility and perfusion. The drug is generally well tolerated and the evidence so far is encouraging, with a clear clinical benefit achieved in the target groups. Its main strength is that it does not appear to affect either heart rate or blood pressure. This review provides an insight into this treatment option, describes the clinical trials evidence, proposed mechanism of action, and pharmacokinetics, and outlines the indications for its use in chronic stable angina.

This is a preview of subscription content, log in via an institution to check access.

Access this article

Log in via an institution

Price excludes VAT (USA)
Tax calculation will be finalised during checkout.

Instant access to the full article PDF.

Institutional subscriptions

Similar content being viewed by others

References

  1. Daly CA, Stavola BD, Sendon JLL, et al. Predicting prognosis in stable angina - results from the Euro heart survey of stable angina: prospective observational study. BMJ. 2006;332:262–267.

    Article  PubMed  Google Scholar 

  2. Fox K, Garcia MA, Ardissino D, et al. Guidelines on the management of stable angina pectoris: executive summary. The Task Force on the Management of Stable Angina Pectoris of the European Society of Cardiology. Eur Heart J. 2006;27:1341–1381.

    Article  PubMed  Google Scholar 

  3. Peterson E. The course of angina: pathophysiology, incidence, therapies & moving beyond mortality. Clin Cardiol. 2007;30(suppl. I):10–15.

    Article  Google Scholar 

  4. Serruys PW, Unger F, Sousa JE, et al. Comparison of coronary-artery bypass surgery and stenting for the treatment of multivessel disease. N Engl J Med. 2001;334:1117–1124.

    Article  Google Scholar 

  5. Holubkov R, Lashkey WK, Haviland A, et al. Angina 1 year after percutaneous coronary intervention: a report from the NHLBI Dynamic Registry. Am Heart J. 2002;144:826–833.

    PubMed  Google Scholar 

  6. Boden WE, O’Rourke RA, Teo KK, et al. Optimal medical therapy with or without PCI for stable coronary disease. N Engl J Med. 2007;356:1503–1516.

    Article  CAS  PubMed  Google Scholar 

  7. Pocock SJ, Henderson RA, Clayton, et al. Quality of life after coronary angioplasty or continued medical treatment for angina: three-year follow up in the RITA-2 trial. J Am Coll Cardiol. 2000;35:907–914.

    Article  CAS  PubMed  Google Scholar 

  8. Henderson RA, Pocock SJ, Clayton TC, et al. Seven-year outcome in the RITA-2 trial: coronary angioplasty versus medical therapy. J Am Coll Cardiol. 2003;42:1161–1170.

    Article  PubMed  Google Scholar 

  9. Joint Formulary Committee. British National Formulary 58: September 2009. Pharmaceutical Press; 2009. Section 2.4, pp. 86–88; Section 2.6.2, pp. 114–115; Section 2.6.3, pp. 121; Section 2.6.1, pp. 111–112; Section 2.6.3,p. 120.

  10. Chaitman BR, Skettino SL, Parker JO, et al. MARISA investigators. Anti-ischemic effects and long-term survival during ranolazine monotherapy in patients with chronic severe angina. J Am Coll Cardiol. 2004;43:1375–1382.

    Article  CAS  PubMed  Google Scholar 

  11. Chaitman BR, Pepine CJ, Parker JO, et al. Combination Assessment of Ranolazine In Stable Angina (CARISA) investigators. Effects of ranolazine with atenolol, amlodipine, or diltiazem on exercise tolerance and angina frequency in patients with severe chronic angina. A randomized controlled trial. JAMA. 2004;291:309–316.

    Article  CAS  PubMed  Google Scholar 

  12. Stone PH, Gratsiansky NA, Blokhin A, et al. ERICA investigators. Antianginal effects of ranolazine when added to treatment with amlodipine: the ERICA (Efficiency of Ranolazine in Chronic Angina) trial. J Am Coll Cardiol. 2006;48:566–575.

    Article  CAS  PubMed  Google Scholar 

  13. Morrow DA, Scirica BM, Karwatowska-Prokopczuk E, et al. MERLIN-TIMI Investigators. Effects of ranolazine on recurrent cardiovascular events in patients with non-ST-elevation acute coronary syndromes. The MERLIN-TIMI 36 randomized trial. JAMA. 2007;297:1775–1783.

    Article  CAS  PubMed  Google Scholar 

  14. Timmis AD, Bernard R, Chaitman BR, et al. Effects of ranolazine on exercise tolerance and HbA1c in patients with chronic angina and diabetes. Eur Heart J. 2006;27:42–48.

    Article  CAS  PubMed  Google Scholar 

  15. Bartnik M, Malmberg K, Hamsten A, et al. Abnormal glucose tolerance - a common risk factor in patients with acute myocardial infarction in comparison with population-based controls. J Intern Med. 2004;256:288–297.

    Article  CAS  PubMed  Google Scholar 

  16. European Medicines Agency. CHMP assessment report for LATIXA. Evaluation of medicines for human use. 2008. Doc. ref.: EMEA/CHMP/30876/2008. London: European Medicines Agency.

    Google Scholar 

  17. Antzelevitch C, Belardinelli L, Zygmunt AC, et al. Electrophysiological effects of ranolazine, a novel antianginal agent with antiarrythmic properties. Circulation. 2004;110:904–910.

    Article  CAS  PubMed  Google Scholar 

  18. Belardinelli L, Antzelevitch C, Fraser H. Inhibition of late (sustained/persistent) sodium current: a potential drug target to reduce intracellular sodium-dependent calcium overload and its detrimental effects on cardiomyocyte function. Eur Heart J. 2004;6(suppl. 1):13–17.

    Google Scholar 

  19. Wu L, Shryock JC, Song Y, et al. Antiarrhythmic effects of ranolazine in a guinea pig in vitro model of long-QT syndrome. J Pharmacol Exper Ther. 2004;310:599–605.

    Article  CAS  Google Scholar 

  20. Fraser H, Belardinelli L, Wang L, et al. Ranolazine decreases diastolic calcium accumulation caused by ATX-II or ischemia in rat hearts. J Mol Cell Cardiol. 2006;41:1031–1038.

    Article  CAS  PubMed  Google Scholar 

  21. Murphy E, Cross H, Steenbergen C. Sodium regulation during ischemia versus reperfusion and its role in injury. Circ Res. 1999;84:1469–1470.

    CAS  PubMed  Google Scholar 

  22. Belardinelli L, Shyrock JC, Fraser H. The mechanism of ranolazine action to reduce ischemia-induced diastolic dysfunction. Eur Heart J. 2006;8(suppl. A):10–13.

    Google Scholar 

  23. Hale SL, Leeka JA, Kloner RA. Improved left ventricular function and reduced necrosis after myocardial ischemia/reperfusion in rabbits treated with ranolazine, an inhibitor of the late sodium channel. J Pharmacol Exper Ther. 2006;318:418–423.

    Article  CAS  Google Scholar 

  24. Ranexa [summary of product characteristics]. November 2008. Wooburn Green, Buckinghamshire: A. Menarini Pharma UK S.R.L. Available at: www.medicines.org.uk/emc/document.aspx?documentid=21402&docType=SPC. Accessed April 14, 2010.

  25. Ranexa [product monograph]. November 2008. Wooburn Green, Buckinghamshire: A. Menarini Pharma U.K. S.R.L. Available at: www.mims.co.uk/Drugs/cardiovascular-system/angina/ranexa. Accessed April 14, 2010.

  26. Belardinelli L, Shryock JC, Wu L, et al. Use of preclinical assays to predict risk of drug-induced torsades de pointes. Heart Rhythm. 2005;2(suppl. 2):S16–S22.

    Article  PubMed  Google Scholar 

Download references

Author information

Authors and Affiliations

  1. Division of Cardiovascular Medicine, University Hospital, Nottingham, NG7 2UH, UK

    Sajid Aslam & David Gray

Authors
  1. Sajid Aslam
    View author publications

    You can also search for this author in PubMed Google Scholar

  2. David Gray
    View author publications

    You can also search for this author in PubMed Google Scholar

Corresponding author

Correspondence to David Gray.

Rights and permissions

Reprints and permissions

About this article

Cite this article

Aslam, S., Gray, D. Ranolazine (Ranexa®) in the treatment of chronic stable angina. Adv Therapy 27, 193–201 (2010). https://doi.org/10.1007/s12325-010-0018-5

Download citation

  • Received:

  • Published:

  • Issue Date:

  • DOI: https://doi.org/10.1007/s12325-010-0018-5

Keywords

Search

Navigation